The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II trial of olaparib and durvalumab in patients with recurrent IDH-mutated gliomas.
 
Xin Wang
No Relationships to Disclose
 
Yosef Ellenbogen
No Relationships to Disclose
 
Christianne Mojica
No Relationships to Disclose
 
Gustavo Duarte Ramos Matos
No Relationships to Disclose
 
Roa Alsajjan
No Relationships to Disclose
 
Ronald Ramos
No Relationships to Disclose
 
Seth Andrew Climans
No Relationships to Disclose
 
Mathew Voisin
No Relationships to Disclose
 
Vikas Patil
No Relationships to Disclose
 
Stephanie Baker
No Relationships to Disclose
 
Yin-Ling Chan
No Relationships to Disclose
 
Thiago Pimentel Muniz
No Relationships to Disclose
 
Andrew Gao
No Relationships to Disclose
 
Ben X Wang
No Relationships to Disclose
 
Gelareh Zadeh
No Relationships to Disclose
 
Warren P. Mason
Honoraria - Apotex; Bayer; GlaxoSmithKline; Viatris
Consulting or Advisory Role - Novocure; Ono Pharmaceutical
Expert Testimony - Medcan
 
Eric Xueyu Chen
Honoraria - AstraZeneca Canada; Bayer; Eisai; GlaxoSmithKline; Ipsen; Merck; Pfizer; Roche
Research Funding - 1Globe Health Institute; AstraZeneca/MedImmune; Bristol-Myers Squibb; Merck Sharp & Dohme; Mirati Therapeutics; Novartis; Nubiyota; Repare Therapeutics; Roche Canada